Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your experience. Save up to 40% More details

Eisai, Biogen start U.S. accelerated approval for new Alzheimer's drug

Stock MarketsSep 28, 2021 04:42AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
© Reuters. FILE PHOTO: The logo of Eisai Co Ltd is displayed at the company headquarters in Tokyo, Japan, March 8, 2018. REUTERS/Issei Kato

By Julie Steenhuysen

CHICAGO (Reuters) - Japanese drugmaker Eisai Co (OTC:ESALY) on Monday began its application process for its experimental drug for early Alzheimer's disease using an accelerated approval pathway, the same path that helped Eisai's development partner Biogen Inc (NASDAQ:BIIB) win U.S. approval of its medication in June.

The Biogen/Eisai drug Aduhelm was the first Alzheimer's treatment to win approval in nearly 20 years, but the Food and Drug Administration's (FDA) controversial use of the accelerated approval process - which authorizes drugs for severe conditions without strong proof of a benefit to patients - has come under heavy fire.

Biogen and Eisai won authorization for Aduhelm based on evidence that it can reduce brain plaques, a likely contributor to Alzheimer's, rather than convincing proof that it slows progression of the lethal disease. Companies are required to run confirmatory studies to prove the drug works as intended.

Now, Eisai, which leads development on Alzheimer's drug lecanemab, is using evidence from a midstage trial showing its drug candidate removes brain plaques to an even greater degree than Aduhelm, with lower rates of brain swelling.

Eisai intends to learn from its partner's experiences as it works through the regulatory process. Ivan Cheung, president of Eisai's global neurology group, said in an interview the company is being as transparent as possible.

Eisai will submit its application to the FDA on a rolling basis, with the aim of completing the application in the next few months. The company plans to submit data from its midstage trial of 856 volunteers, which showed that 80% of patients had no amyloid left in their brains after 18 months of treatment.

That benefit also correlated with improvements seen in some patients, Cheung said. The trial was published in Alzheimer's Research and Therapy, a peer-reviewed journal, in April.

A key point of contention with the Aduhelm approval is the timing of the confirmatory trial, which FDA officials said could take several years. Eisai already has a confirmatory, Phase III trial fully enrolled. Cheung expects results before the end of 2022.

"We understand the urgency for the public to have validating clinical data," Cheung said.

The FDA initially gave Aduhelm a broad indication that went beyond what was studied in its trials. Cheung said his company only wants the FDA to consider the drug's exact study population - early Alzheimer's.

Eli Lilly (NYSE:LLY) and Co said in July it also plans to seek accelerated approval for its Alzheimer's candidate, donanemab, based on mid-stage data. Lilly has said it plans to seek U.S. regulatory approval by yearend.

Eisai, Biogen start U.S. accelerated approval for new Alzheimer's drug

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
Sign up with Email